Download PDF
Semin Liver Dis 2018; 38(02): 112-120
DOI: 10.1055/s-0038-1655774
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Management of HCV-Related Liver Disease in Hemophilia and Thalassemia

Maria Grazia Rumi
1   Hepatology Unit,Ospedale San Giuseppe and University of Milan, Milan, Italy
,
Vito Di Marco
2   Gastroenterology and Hepatology Unit, Azienda Universitaria Ospedaliera Policlinico and University of Palermo, Palermo, Italy
,
Massimo Colombo
3   Department of Medicine, Clinical and Research Center, Humanitas Hospital, Rozzano, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
05 June 2018 (online)

    Permissions and Reprints

Abstract

Chronic infection with the hepatitis C virus (HCV) has long been the dominant complication of substitution therapy in patients with inherited blood disorders and the cause of anticipated death due to end-stage liver disease. In hemophilia, transmission of HCV with clotting factors concentrates started to be curbed in the mid-1980s following the adoption of procedures of virus inactivation of concentrates based on heat, whereas in the 1990s treatment of HCV infection with interferon monotherapy was attempted, however, with little success. The advent of combination therapy of interferon with ribavirin led to a substantial improvement of treatment outcome (40% rate of cure), that however was still of limited efficacy in patients with advanced liver disease, those with high load of HCV genotype 1, and patients coinfected with the human immunodeficiency virus. In this latter population, while the course of hepatitis C was accelerated as a consequence of immunodeficiency, the advent of highly active antiretroviral therapy led acquired immunodeficiency syndrome (AIDS) to decline and hepatitis C to progressively emerge as a dominant cause of mortality, in parallel. In patients with thalassemia, transfusion-related transmission of HCV was efficiently interrupted in 1992 with the advent of sensitive screening tests for testing donors for HCV, whereas treatment with interferon and ribavirin of infected thalassemics was constrained by an increased risk of anemia due to the hemolytic properties of ribavirin coupled with interferon-induced bone marrow suppression. The advent of safe and potent regimens based on the oral administration of direct antiviral agents has revolutionized therapy of HCV in patients with congenital blood diseases, providing substantial clinical benefits and making elimination of infection in these populations, possible.

Keywords

hepatitis C - hemophilia - sickle cell anemia - thalassemia - direct antiviral agents
 

  • References

  • 1 Rumi MG, Colombo M, Gringeri A, Mannucci PM. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. Ann Intern Med 1990; 112 (05) 379-380
    CrossrefPubMedGoogle Scholar
  • 2 Makris M, Preston FE, Triger DR. , et al. Hepatitis C antibody and chronic liver disease in haemophilia. Lancet 1990; 335 (8698): 1117-1119
    CrossrefPubMedGoogle Scholar
  • 3 Mannucci PM, Ronchi G, Rota L, Colombo M. Liver biopsy in hemophilia. Ann Intern Med 1978; 88 (03) 429-430
    PubMedGoogle Scholar
  • 4 Colombo M, Rumi MG. Liver disease and pathology in hemophilia. Scand J Haematol Suppl 1984; 40: 341-348
    PubMedGoogle Scholar
  • 5 Theodore D, Fried MW, Kleiner DE. , et al. Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. Haemophilia 2004; 10 (05) 413-421
    CrossrefPubMedGoogle Scholar
  • 6 Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. ; Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood 2004; 104 (01) 34-39
    CrossrefPubMedGoogle Scholar
  • 7 Posthouwer D, Makris M, Yee TT. , et al. Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. Blood 2007; 109 (09) 3667-3671
    CrossrefPubMedGoogle Scholar
  • 8 Orman ES, Fried MW. Hepatitis C viral infection in patients with hemophilia and hemolytic disorders. Clin Liver Dis 2012; 1: 95-97
    CrossrefPubMedGoogle Scholar
  • 9 Di Marco V, Capra M, Angelucci E. , et al; Italian Society for the Study of Thalassemia and Haemoglobinopathies; Italian Association for the Study of the Liver. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood 2010; 116 (16) 2875-2883
    CrossrefPubMedGoogle Scholar
  • 10 Mannucci PM, Colombo M. Virucidal treatment of clotting factor concentrates. Lancet 1988; 2 (8614): 782-785
    PubMedGoogle Scholar
  • 11 Mannucci PM, Schimpf K, Brettler DB. , et al; International Study Group. Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. Ann Intern Med 1990; 113 (01) 27-32
    CrossrefPubMedGoogle Scholar
  • 12 Hermans C, Altisent C, Batorova A. , et al; European Haemophilia Therapy Standardisation Board. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia 2009; 15 (03) 639-658
    CrossrefPubMedGoogle Scholar
  • 13 Franchini M, Nicolini N, Capra F. Treatment of hepatitis C in hemophiliacs. Am J Hematol 2006; 81 (09) 696-702
    CrossrefPubMedGoogle Scholar
  • 14 Posthouwer D, Mauser-Bunschoten EP, Fischer K, Makris M. Treatment of chronic hepatitis C in patients with haemophilia: a review of the literature. Haemophilia 2006; 12 (05) 473-478
    CrossrefPubMedGoogle Scholar
  • 15 Tagliaferri A, Rivolta GF, Iorio A. , et al; Italian Association of Hemophilia Centers. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16 (03) 437-446
    PubMedGoogle Scholar
  • 16 Rumi MG, Colombo M, Romeo R, Colucci G, Gringeri A, Mannucci PM. Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients. Blood 1990; 75 (08) 1654-1658
    PubMedGoogle Scholar
  • 17 Soriano V, Sulkowski M, Bergin C. , et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16 (06) 813-828
    CrossrefPubMedGoogle Scholar
  • 18 Goedert JJ, Eyster ME, Lederman MM. , et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100 (05) 1584-1589
    PubMedGoogle Scholar
  • 19 Colombo M, Mannucci PM, Brettler DB. , et al. Hepatocellular carcinoma in hemophilia. Am J Hematol 1991; 37 (04) 243-246
    CrossrefPubMedGoogle Scholar
  • 20 Tradati F, Colombo M, Mannucci PM. , et al; The Study Group of the Association of Italian Hemophilia Centers. A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C. Blood 1998; 91 (04) 1173-1177
    PubMedGoogle Scholar
  • 21 Santagostino E, Colombo M, Rivi M. , et al; Study Group of the Association of Italian Hemophilia Centers. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003; 102 (01) 78-82
    CrossrefPubMedGoogle Scholar
  • 22 Ragni MV, Humar A, Stock PG. , et al. Hemophilia liver transplantation observational study. Liver Transpl 2017; 23 (06) 762-768
    CrossrefPubMedGoogle Scholar
  • 23 Belli LS, Duvoux C, Berenguer M. , et al. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol 2017; 67 (03) 585-602
    CrossrefPubMedGoogle Scholar
  • 24 Colombo M, Mannucci PM, Carnelli V, Savidge GF, Gazengel C, Schimpf K. Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet 1985; 2 (8445): 1-4
    PubMedGoogle Scholar
  • 25 Mannucci PM, Gdovin S, Gringeri A. , et al; The Italian Collaborative Group. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann Intern Med 1994; 120 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 26 Makris M, Preston FE, Triger DR, Underwood JC, Westlake L, Adelman MI. A randomized controlled trial of recombinant interferon-α in chronic hepatitis C in hemophiliacs. Blood 1991; 78 (07) 1672-1677
    PubMedGoogle Scholar
  • 27 Bresters D, Mauser-Bunschoten EP, Cuypers HT. , et al. Long term treatment of chronic hepatitis C with interferon alfa-2b: disappearance of HCV-RNA in a pilot study of eight haemophilia patients. Gut 1993; 34 (2, Suppl): S124-S125
    CrossrefPubMedGoogle Scholar
  • 28 Peerlinck K, Willems M, Sheng L. , et al. Rapid clearance of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with clotting disorders and chronic hepatitis C treated with alpha-2b interferon is not a predictor for sustained response to treatment. Br J Haematol 1994; 86 (04) 816-819
    CrossrefPubMedGoogle Scholar
  • 29 Telfer P, Devereux H, Colvin B, Hayden S, Dusheiko G, Lee C. Alpha interferon for hepatitis C virus infection in haemophilic patients. Haemophilia 1995; 1 (01) 54-58
    CrossrefPubMedGoogle Scholar
  • 30 Yoshikawa M, Fukui H, Kojima H. , et al. Interferon treatment of chronic hepatitis C in patients with hemophilia or von Willebrand's disease in Japan. J Gastroenterol 1995; 30 (03) 367-371
    CrossrefPubMedGoogle Scholar
  • 31 Yamada M, Fukuda Y, Koyama Y. , et al. A long-term follow-up study of interferon treatment for chronic hepatitis C in Japanese patients with congenital bleeding disorders. Eur J Haematol 1996; 57 (02) 165-170
    PubMedGoogle Scholar
  • 32 Hanley JP, Jarvis LM, Andrew J. , et al. Interferon treatment for chronic hepatitis C infection in hemophiliacs--influence of virus load, genotype, and liver pathology on response. Blood 1996; 87 (05) 1704-1709
    PubMedGoogle Scholar
  • 33 Rumi MG, Santagostino E, Morfini M. , et al; Hepatitis Study Group of the Association of Italian Hemophilia Centers. A multicenter controlled, randomized, open trial of interferon α2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Blood 1997; 89 (10) 3529-3533
    PubMedGoogle Scholar
  • 34 Pinilla J, Quintana M, Magallon M. High-dose and long-term therapy of α interferon in hemophiliac patients with chronic C virus hepatitis. Blood 1998; 91 (02) 727-728
    PubMedGoogle Scholar
  • 35 Laursen AL, Scheibel E, Ingerslev J. , et al. Alpha interferon therapy in Danish haemophiliac patients with chronic hepatitis C: results of a randomized controlled open label study comparing two different maintenance regimens following standard interferon-alpha-2b treatment. Haemophilia 1998; 4 (01) 25-32
    CrossrefPubMedGoogle Scholar
  • 36 Adamowicz-Salach A, Pawelec K, Loch T. , et al. Incidence and treatment of hepatitis C virus infection in children with haemophilia in Poland. Haemophilia 1999; 5 (06) 436-440
    CrossrefPubMedGoogle Scholar
  • 37 Hayashi K, Fukuda Y, Nakano I. , et al. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs. Haemophilia 2000; 6 (06) 677-681
    CrossrefPubMedGoogle Scholar
  • 38 Beurton I, Bertrand MA, Bresson-Hadni S. , et al. Interferon alpha therapy in haemophilic patients with chronic hepatitis C: a French multicentre pilot study of 58 patients. Eur J Gastroenterol Hepatol 2001; 13 (07) 859-864
    CrossrefPubMedGoogle Scholar
  • 39 Hanabusa H. Efficacy of induction therapy with high-dose interferon for patients with hemophilia and human immunodeficiency virus-hepatitis C virus coinfection. Clin Infect Dis 2002; 35 (12) 1527-1533
    CrossrefPubMedGoogle Scholar
  • 40 Shields PL, Mutimer DJ, Muir D. , et al. Combined alpha interferon and ribavirin for the treatment of hepatitis C in patients with hereditary bleeding disorders. Br J Haematol 2000; 108 (02) 254-258
    CrossrefPubMedGoogle Scholar
  • 41 Sauleda S, Esteban JI, Altisent C, Puig L, Esteban R, Guardia J. Treatment with interferon plus ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C. Thromb Haemost 2000; 83 (06) 807-810
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Fried MW, Peter J, Hoots K. , et al. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology 2002; 36 (4 Pt 1): 967-972
    CrossrefPubMedGoogle Scholar
  • 43 Santagostino E, De Filippi F, Rumi MG, Rivi M, Colombo M, Mannucci PM. ; Hepatitis Study Group of the Association of Italian Hemophilia Centers. Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients. Transfusion 2004; 44 (05) 790-794
    CrossrefPubMedGoogle Scholar
  • 44 Santagostino E, Rumi MG, Rivi M, Colombo M, Mannucci PM. ; Hepatitis Study Group of the Association of Italian Hemophilia Centers. Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy. Blood 2002; 99 (03) 1089-1091
    CrossrefPubMedGoogle Scholar
  • 45 Franchini M, Tagliaferri A, Rossetti G. , et al. Interferon and ribavirin in HIV-negative haemophiliacs with chronic hepatitis C who were nonresponders to a previous interferon treatment. Haemophilia 2002; 8 (06) 794-797
    CrossrefPubMedGoogle Scholar
  • 46 Mancuso ME, Santagostino E, Linari S. , et al. Sustained suppression of hepatitis C by pegylated interferon (pegIFN) and ribavirin in hemophilic patients. Haemophilia 2004; 10: S48
    PubMedGoogle Scholar
  • 47 Theodossiades G, Nomikou E, Tsevrenis V. , et al. Treatment with peg-interferon alpha-2b and ribavirin in patients with congenital hemorrhagic disorders and HCV infection. Haemophilia 2004; 10: S50
    PubMedGoogle Scholar
  • 48 Posthouwer D, Yee TT, Makris M. , et al. Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study. J Thromb Haemost 2007; 5 (08) 1624-1629
    CrossrefPubMedGoogle Scholar
  • 49 Pérez-Olmeda M, Núñez M, Romero M. , et al. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17 (07) 1023-1028
    CrossrefPubMedGoogle Scholar
  • 50 Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48 (02) 353-367
    CrossrefPubMedGoogle Scholar
  • 51 Alberti A, Clumeck N, Collins S. , et al; ECC Jury. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42 (05) 615-624
    CrossrefPubMedGoogle Scholar
  • 52 Makris M, Konkle BA. Hepatitis C in haemophilia: time for treatment for all. Haemophilia 2017; 23 (02) 180-181
    CrossrefPubMedGoogle Scholar
  • 53 Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014; 60 (03) 530-537
    CrossrefPubMedGoogle Scholar
  • 54 Ackens R, Posthouwer D. Treatment of chronic hepatitis C with direct acting antiviral agents in patients with haemophilia, end-stage liver disease and coinfected with HIV. Haemophilia 2016; 22 (03) e223-e225
    CrossrefPubMedGoogle Scholar
  • 55 Walsh CE, Workowski K, Terrault NA. , et al. Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders. Haemophilia 2017; 23 (02) 198-206
    CrossrefPubMedGoogle Scholar
  • 56 Nagao A, Hanabusa H. Brief report: the impact of ledipasvir/sofosbuvir on HIV-positive and HIV-negative Japanese hemophilia patients with 1, 4, and mixed-genotype HCV. J Acquir Immune Defic Syndr 2017; 74 (04) 418-422
    CrossrefPubMedGoogle Scholar
  • 57 Stedman CAM, Hyland RH, Ding X, Pang PS, McHutchison JG, Gane EJ. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia 2015; 22: 214-217
    PubMedGoogle Scholar
  • 58 Lee HW, Yoo KY, Won JW, Kim HJ. Direct acting antiviral agents in Korean patients with chronic hepatitis C and hemophilia who are treatment-naïve or treatment-experienced. Gut Liver 2017; 11 (05) 721-727
    CrossrefPubMedGoogle Scholar
  • 59 Hézode C, Colombo M, Bourlière M. , et al; C-EDGE IBLD Study Investigators. Elbasvir/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III study. Hepatology 2017; 66 (03) 736-745
    CrossrefPubMedGoogle Scholar
  • 60 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017; 66 (01) 153-164
    CrossrefPubMedGoogle Scholar
  • 61 Bourlière M, Gordon SC, Flamm SL. , et al; POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 2017; 376 (22) 2134-2146
    CrossrefPubMedGoogle Scholar
  • 62 Zeuzem S, Foster GR, Wang S. , et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018; 378 (04) 354-369
    CrossrefPubMedGoogle Scholar
  • 63 Olivieri NF, Nathan DG, MacMillan JH. , et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331 (09) 574-578
    CrossrefPubMedGoogle Scholar
  • 64 Borgna-Pignatti C, Rugolotto S, De Stefano P. , et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89 (10) 1187-1193
    PubMedGoogle Scholar
  • 65 Olivieri NF, Brittenham GM, Matsui D. , et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995; 332 (14) 918-922
    CrossrefPubMedGoogle Scholar
  • 66 Cappellini MD, Cohen A, Piga A. , et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107 (09) 3455-3462
    CrossrefPubMedGoogle Scholar
  • 67 Laperche S. Blood safety and nucleic acid testing in Europe. Euro Surveill 2005; 10 (02) 3-4
    PubMedGoogle Scholar
  • 68 Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol 2006; 45 (04) 607-616
    CrossrefPubMedGoogle Scholar
  • 69 Prati D, Zanella A, Farma E. , et al. A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous beta-thalassemia. Blood 1998; 92 (09) 3460-3464
    CrossrefPubMedGoogle Scholar
  • 70 Jang TY, Lin PC, Huang CI. , et al. Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients. PLoS One 2017; 12 (06) e0178883
    CrossrefPubMedGoogle Scholar
  • 71 Ahmed Kiani R, Anwar M, Waheed U, Asad MJ, Abbasi S, Abbas Zaheer H. Epidemiology of transfusion transmitted infection among patients with β-thalassaemia major in Pakistan. J Blood Transfus 2016; 2016: 8135649
    CrossrefPubMedGoogle Scholar
  • 72 Jafroodi M, Davoudi-Kiakalayeh A, Mohtasham-Amiri Z, Pourfathollah AA, Haghbin A. Trend in prevalence of hepatitis C virus infection among β-thalassemia major patients: 10 years of experience in Iran. Int J Prev Med 2015; 6: 89 . Doi: 10.4103/2008-7802.164832
    CrossrefPubMedGoogle Scholar
  • 73 Al-Naamani K, Al-Zakwani I, Al-Sinani S, Wasim F, Daar S. Prevalence of hepatitis C among multi-transfused thalassaemic patients in Oman: single centre experience. Sultan Qaboos Univ Med J 2015; 15 (01) e46-e51
    PubMedGoogle Scholar
  • 74 Chakrabarty P, Rudra S, Hossain MA. Prevalence of HBV and HCV among the multi-transfused beta thalassemic major patients in a day care centre of blood transfusion department of Mymensingh Medical College Hospital. Mymensingh Med J 2014; 23 (02) 235-241
    PubMedGoogle Scholar
  • 75 Hussein E. Evaluation of infectious disease markers in multitransfused Egyptian children with thalassemia. Ann Clin Lab Sci 2014; 44 (01) 62-66
    PubMedGoogle Scholar
  • 76 Mansour AK, Aly RM, Abdelrazek SY. , et al. Prevalence of HBV and HCV infection among multi-transfused Egyptian thalassemic patients. Hematol Oncol Stem Cell Ther 2012; 5 (01) 54-59
    CrossrefPubMedGoogle Scholar
  • 77 Al-Sweedan SA, Jaradat S, Amer K, Hayajneh W, Haddad H. Seroprevalence and genotyping of hepatitis C virus in multiple transfused Jordanian patients withß-thalassemia major. Turk J Haematol 2011; 28 (01) 47-51
    PubMedGoogle Scholar
  • 78 Di Marco V, Bronte F, Calvaruso V. , et al. IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica 2012; 97 (05) 679-686
    CrossrefPubMedGoogle Scholar
  • 79 Borgna-Pignatti C, Cappellini MD, De Stefano P. , et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107 (09) 3733-3737
    CrossrefPubMedGoogle Scholar
  • 80 Pennell DJ, Porter JB, Cappellini MD. , et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010; 115 (12) 2364-2371
    CrossrefPubMedGoogle Scholar
  • 81 Di Marco V, Capra M, Gagliardotto F. , et al. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica 2008; 93 (08) 1243-1246
    CrossrefPubMedGoogle Scholar
  • 82 Singh S, Muir AJ, Dieterich DT, Falck-Ytter YT. American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases. Gastroenterology 2017; 152 (06) 1544-1577
    CrossrefPubMedGoogle Scholar
  • 83 Di Marco V, Bronte F, Cabibi D. , et al. Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. Br J Haematol 2010; 148 (03) 476-479
    CrossrefPubMedGoogle Scholar
  • 84 Fraquelli M, Cassinerio E, Roghi A. , et al. Transient elastography in the assessment of liver fibrosis in adult thalassemia patients. Am J Hematol 2010; 85 (08) 564-568
    CrossrefPubMedGoogle Scholar
  • 85 Sarigianni M, Liakos A, Vlachaki E. , et al. Accuracy of magnetic resonance imaging in diagnosis of liver iron overload: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015; 13 (01) 55-63.e5
    CrossrefPubMedGoogle Scholar
  • 86 Angelucci E, Muretto P, Nicolucci A. , et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002; 100 (01) 17-21
    CrossrefPubMedGoogle Scholar
  • 87 Perifanis V, Tziomalos K, Tsatra I, Karyda S, Patsiaoura K, Athanassiou-Metaxa M. Prevalence and severity of liver disease in patients with b thalassemia major. A single-institution fifteen-year experience. Haematologica 2005; 90 (08) 1136-1138
    PubMedGoogle Scholar
  • 88 Simonetti RG, Cammà C, Fiorello F. , et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 1992; 116 (02) 97-102
    CrossrefPubMedGoogle Scholar
  • 89 Borgna-Pignatti C, Vergine G, Lombardo T. , et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 2004; 124 (01) 114-117
    CrossrefPubMedGoogle Scholar
  • 90 Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin 2006; 30 (01) 119-124
    CrossrefPubMedGoogle Scholar
  • 91 Borgna-Pignatti C, Garani MC, Forni GL. , et al. Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. Br J Haematol 2014; 167 (01) 121-126
    CrossrefPubMedGoogle Scholar
  • 92 Di Marco V, Lo Iacono O, Almasio P. , et al. Long-term efficacy of alpha-interferon in beta-thalassemics with chronic hepatitis C. Blood 1997; 90 (06) 2207-2212
    PubMedGoogle Scholar
  • 93 Di Marco V, D'Ambrosio R, Bronte F. , et al; on behalf ITHACA (Italy for THAalassemia, hepatitis C Advances) Group. Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: is there still an indication?. Dig Liver Dis 2016; 48 (06) 650-655
    CrossrefPubMedGoogle Scholar
  • 94 Sinakos E, Kountouras D, Koskinas J. , et al. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease. Br J Haematol 2017; 178 (01) 130-136
    CrossrefPubMedGoogle Scholar
  • 95 Mangia A, Sarli R, Gamberini R. , et al. Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection. Aliment Pharmacol Ther 2017; 46 (04) 424-431
    CrossrefPubMedGoogle Scholar
  • 96 Origa R, Ponti ML, Filosa A. , et al; Italy for THAlassemia and hepatitis C Advance - Società Italiana Talassemie ed Emoglobinopatie (ITHACA-SITE). Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. Am J Hematol 2017; 92 (12) 1349-1355
    CrossrefPubMedGoogle Scholar
  • 97 Nagral A, Sawant S, Nagral N, Parikh P, Malde P, Merchant R. Generic direct acting antivirals in treatment of chronic hepatitis C infection in patients of thalassemia major. J Clin Exp Hepatol 2017; 7 (03) 172-178
    CrossrefPubMedGoogle Scholar
  • 98 Hill A, Khwairakpam G, Wang J. , et al. High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C. J Virus Erad 2017; 3 (04) 200-203
    PubMedGoogle Scholar
  • 99 D'Ambrosio R, Lampertico P. Editorial: good news to patients with thalassaemia-HCV clearance made easy with direct-acting antivirals. Aliment Pharmacol Ther 2017; 46 (06) 628-629
    CrossrefPubMedGoogle Scholar
  • 100 Lazarus JV, Wiktor S, Colombo M, Thursz M. ; EASL International Liver Foundation. Micro-elimination - a path to global elimination of hepatitis C. J Hepatol 2017; 67 (04) 665-666
    CrossrefPubMedGoogle Scholar